Table 2 Comparison of baseline characteristics in patients with high RVP, low RVP, and intermediate RVP
Patient characteristics | Group A; 100% RV pacing (n = 16) | Group B; ≤ 1% RV pacing (n = 29) | Group C; > 1–< 100% RV pacing (n = 60) | p value |
|---|---|---|---|---|
Age (years) | 75 ± 3.5 | 68 ± 1.8 | 80 ± 1.2 | < 0.0001 |
Gender (female) | 50% | 72% | 42% | 0.02 |
Hypertension | 81% | 72% | 90% | ns |
Diabetes mellitus | 25% | 17% | 27% | ns |
Coronary artery disease | 44% | 41% | 53% | ns |
Trans-aortic valve replacement | 25% | 3% | 12% | ns |
Cardiac bypass/valve surgery | 31% | 17% | 23% | ns |
Baseline LVEF% | 60 ± 1.4 | 62 ± 1.3 | 57 ± 1 | 0.005 |
Beta-blocker use | 19% | 38% | 50% | ns |
Calcium channel blocker use | 6% | 7% | 7% | ns |
Antiarrhythmic medication use | 0% | 7% | 18% | ns |
De novo pacemaker implant | 56% | 48% | 48% | ns |
Indication for pacemaker | 94% (AVB) | 7% (AVB) | 53% (AVB) | < 0.0001 |
6% (SSS) | 93% (SSS) | 47% (SSS) | ||
Duration of analysis (days) | 1029 ± 67 | 1076 ± 38 | 1033 ± 32 | ns |
Pacemaker company | 50% (MDT) 50% (BS) | 69% (MDT) 31% (BS) | 65% (MDT) 35% (BS) | ns |
Programmed mode of pacing | 100% (DDD) | 31% (DDD) | 62% (DDD) | < 0.0001 |
0% (MVP) | 69% (MVP) | 23% (MVP) | ||
0% (VVI and DDI) | 0% (VVI and DDI) | 15% (VVI and DDI) | ||
Minimum pacing rate (n/min) | 61 ± 1 | 59 ± 1 | 60 ± 0.5 | ns |
Maximum tracking rate (n/min) | 127 ± 2.4 | 128.4 ± 1.2 | 126 ± 1.2 | ns |
Rate response present | 50% | 76% | 70% | ns |